Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1

Open access
Starr, Stuart E., Fletcher, Courtney V., Spector, Stephen A., Yong, Florence H., Fenton, Terence, Brundage, Richard C., Manion, Douglas, Ruiz, Nancy M., Gersten, Merril, Becker, Mark, McNamara, James, Purdue, Lynette, Siminski, Suzanne, Graham, Bobbie, Kornhauser, David M., Fiske, William, Vincent, Carol, Lischner, Harold W., Dankner, Wayne M., Flynn, Patricia M., Mofenson, Lynne M. · 1999 · New England Journal of Medicine

Abstract

BACKGROUND: Consistent long-term viral suppression has been difficult to achieve in children with human immunodeficiency virus type 1 (HIV-1) infection. We tested the safety and antiviral efficacy of a novel combination consisting of efavirenz, nelfinavir, and one or more nucleoside reverse-transcriptase inhibitors in 57 children previously treated with only nucleoside reverse-transcriptase inhibitors. METHODS: The children were monitored for 48 weeks after the initiation of therapy. We assessed plasma concentrations of efavirenz and nelfinavir, plasma HIV-1 RNA levels, and lymphocyte subpopulations. RESULTS: At base line, the 57 HIV-1-infected children (age range, 3.8 to 16.8 years) had a median of 699 CD4 cells per cubic millimeter and 10,000 copies of HIV-1 RNA per milliliter of plasma. The most common treatment-related effects of at least moderate severity were rash (in 30 percent of children), diarrhea (in 18 percent), neutropenia (in 12 percent), and biochemical abnormalities (in 12 percent). Serious side effects were uncommon. The mean values for the area under the curve for efavirenz and nelfinavir corresponded to expected values. In an intention-to-treat analysis, 76 percent of children had plasma HIV-1 RNA levels of less than 400 copies per milliliter after 48 weeks of therapy and 63 percent had levels of less than 50 copies per milliliter. A high plasma HIV-1 RNA level at base line significantly decreased the likelihood that plasma levels of HIV-1 RNA would become undetectable during treatment. CONCLUSIONS: In HIV-1-infected children who were previously treated with nucleoside reverse-transcriptase inhibitors, the combination of efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors was generally well tolerated and had a potent and sustained antiviral effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199912163412502

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 209

Metadata

Authors
Starr, S. E., Fletcher, C. V., Spector, S. A., Yong, F. H., Fenton, T., Brundage, R. C., Manion, D., Ruiz, N. M., Gersten, M., Becker, M., McNamara, J., Purdue, L., Siminski, S., Graham, B., Kornhauser, D. M., Fiske, W., Vincent, C., Lischner, H. W., Dankner, W. M., Flynn, P. M., & Mofenson, L. M.
Venue
New England Journal of Medicine
Published
1999-12-16
Volume
341
Issue
25
Pages
1874-1881
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2318180004
Cited by
209
References
1
FWCI
10.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. https://app.cochat.ai/papers/10.1056/nejm199912163412502
The paper
Starr, S. E., Fletcher, C. V., Spector, S. A., Yong, F. H., Fenton, T., Brundage, R. C., Manion, D., Ruiz, N. M., Gersten, M., Becker, M., McNamara, J., Purdue, L., Siminski, S., Graham, B., Kornhauser, D. M., Fiske, W., Vincent, C., Lischner, H. W., Dankner, W. M., . . . Mofenson, L. M. (1999). Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. New England Journal of Medicine. https://doi.org/10.1056/nejm199912163412502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.